Literature DB >> 19454439

Locally recurrent or metastatic breast cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.

F Cardoso1, M Castiglione.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19454439     DOI： 10.1093/annonc/mdp115

Source DB:  PubMed          Journal:  Ann Oncol        ISSN： 0923-7534            Impact factor:   32.976


× No keyword cloud information.
  16 in total

1.  SEOM clinical guidelines for the management of metastatic breast cancer 2013.

Authors:  A Llombart Cussac; J de la Haba Rodríguez; A Ruiz Simón; I Álvarez López; J Cortés Castán
Journal:  Clin Transl Oncol       Date:  2013-10-23       Impact factor: 3.405

2.  Extra-mammary findings in breast MRI.

Authors:  Pierluigi Rinaldi; M Costantini; P Belli; M Giuliani; E Bufi; R Fubelli; D Distefano; M Romani; L Bonomo
Journal:  Eur Radiol       Date:  2011-06-18       Impact factor: 5.315

Review 3.  Primary metastatic breast cancer: the impact of locoregional therapy.

Authors:  Steffi Hartmann; Toralf Reimer; Bernd Gerber; Angrit Stachs
Journal:  Breast Care (Basel)       Date:  2014-02       Impact factor: 2.860

4.  Diabetes and prognosis in a breast cancer cohort.

Authors:  Michael G Schrauder; Peter A Fasching; Lothar Häberle; Michael P Lux; Claudia Rauh; Alexander Hein; Christian M Bayer; Katharina Heusinger; Arndt Hartmann; Johanna D Strehl; David L Wachter; Rüdiger Schulz-Wendtland; Boris Adamietz; Matthias W Beckmann; Christian R Loehberg
Journal:  J Cancer Res Clin Oncol       Date:  2010-12-05       Impact factor: 4.553

5.  Sublingual Nodules: Diagnostic Markers of Metastatic Breast Cancer.

Authors:  Xue Yang; Cui-Hong Zhu; Rui Cao; Jian Hao; Xiong-Zhi Wu
Journal:  Chin J Integr Med       Date:  2018-04-17       Impact factor: 1.978

6.  Clinical outcomes of women with metastatic breast cancer treated with nab-paclitaxel: experience from a single academic cancer centre.

Authors:  S Dent; J Fraser; N Graham; M Campbell; S Hopkins; G Dranitsaris
Journal:  Curr Oncol       Date:  2013-02       Impact factor: 3.677

7.  Anthracycline rechallenge using pegylated liposomal doxorubicin in patients with metastatic breast cancer: a pooled analysis using individual data from four prospective trials.

Authors:  S-E Al-Batran; M Güntner; C Pauligk; M Scholz; R Chen; B Beiss; S Stopatschinskaja; W Lerbs; N Harbeck; E Jäger
Journal:  Br J Cancer       Date:  2010-10-26       Impact factor: 7.640

8.  Safety and Efficacy of Tien-Hsien Liquid Practical in Patients with Refractory Metastatic Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase IIa Trial.

Authors:  Wen-Hung Kuo; Chien-An Yao; Chih Hui Lin; King-Jen Chang
Journal:  Evid Based Complement Alternat Med       Date:  2012-04-01       Impact factor: 2.629

9.  miR-139-5p is a regulator of metastatic pathways in breast cancer.

Authors:  Keerthana Krishnan; Anita L Steptoe; Hilary C Martin; Diwakar R Pattabiraman; Katia Nones; Nic Waddell; Mythily Mariasegaram; Peter T Simpson; Sunil R Lakhani; Alexander Vlassov; Sean M Grimmond; Nicole Cloonan
Journal:  RNA       Date:  2013-10-24       Impact factor: 4.942

Review 10.  First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?

Authors:  Alessandra Fabi; Paola Malaguti; Sabrina Vari; Francesco Cognetti
Journal:  J Exp Clin Cancer Res       Date:  2016-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.